换一批Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies.
第一作者：
Ellen,Weisberg
第一单位：
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.;Department of Medicine, Harvard Medical School, Boston, MA, USA.
作者：
医学主题词
苯胺化合物(Aniline Compounds);抗肿瘤药(Antineoplastic Agents);苯咪唑类(Benzimidazoles);苯并噻唑类(Benzothiazoles);细胞系, 肿瘤(Cell Line, Tumor);药物筛选试验, 抗肿瘤(Drug Screening Assays, Antitumor);血液肿瘤(Hematologic Neoplasms);人类(Humans);突变蛋白质类(Mutant Proteins);苯脲化合物(Phenylurea Compounds);哌啶类(Piperidines);蛋白激酶抑制剂(Protein Kinase Inhibitors);原癌基因蛋白质c-cbl(Proto-Oncogene Proteins c-cbl);原癌基因蛋白质类c-kit(Proto-Oncogene Proteins c-kit);吡嗪类(Pyrazines);吡唑类(Pyrazoles);吡咯类(Pyrroles);星状孢子素(Staurosporine);三嗪类(Triazines);fms样酪氨酸激酶3(fms-Like Tyrosine Kinase 3)
DOI
10.1111/bjh.16092
PMID
31309543
发布时间
2021-08-26
- 浏览7
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
